Naporafenib is an investigational medication being studied for its potential to treat patients with a specific type of skin cancer known as NRAS mutant cutaneous melanoma. It is being tested in combination with another medication to see if it can help improve outcomes for patients whose cancer cannot be surgically removed or has spread to other parts of the body.

Trametinib is a medication used to treat certain types of skin cancer. In this trial, it is being used both in combination with naporafenib and as a standalone treatment option. The study aims to determine the effectiveness of trametinib when used alone or in combination with naporafenib.

Dacarbazine is a chemotherapy drug that is used to treat melanoma. In this trial, it is one of the treatment options that doctors can choose for patients. The study is comparing the effectiveness of dacarbazine to other treatments to see which works best for patients with this type of skin cancer.

Temozolomide is another chemotherapy medication that is used to treat melanoma. It is included in the trial as one of the treatment options available to doctors. The trial is evaluating how well temozolomide works compared to other treatments for patients with NRAS mutant cutaneous melanoma.

Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma – This is a type of skin cancer that occurs when melanocytes, the cells responsible for skin pigment, grow uncontrollably. It is characterized by a mutation in the NRAS gene, which can lead to aggressive tumor growth. The term “unresectable” indicates that the cancer cannot be removed completely through surgery. When the disease is metastatic, it means that the cancer has spread from its original site to other parts of the body. The progression of this melanoma can vary, but it often involves the development of new tumors in distant organs. The condition is typically monitored through imaging and clinical evaluations to assess the spread and growth of the cancer.